Biomea Fusion to Evaluate Icovamenib with Semaglutide in Obesity Trial, Citing Synergistic Preclinical Data
BMEA sits 58% above its 52-week low of $0.872.
Summary
Biomea Fusion announced a research collaboration with the University of Leicester to evaluate its lead drug, icovamenib, in combination with semaglutide for obesity. This expands icovamenib's clinical development into a significant new market, following recent positive Phase 2 results in Type 1 Diabetes. The study aims to enhance weight loss while preserving lean mass, addressing a known challenge with GLP-1 therapies, based on promising preclinical data showing synergistic effects. Enrollment for the randomized, double-blinded trial is set to begin in Q3, with primary outcome data expected 24 weeks after enrollment.
At the time of this announcement, BMEA was trading at $1.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $99.1M. The 52-week trading range was $0.87 to $3.08. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.